Dementia is a syndrome caused by multiple diseases and injuries that progressively impair memory, thinking, and the ability to perform daily activities. Alzheimer disease is the most common form, accounting for an estimated 60-70% of cases. Dementia is a major cause of disability and dependency in older adults worldwide.
Studies linked better overall brain health, higher midlife vitamin D levels and lifelong intellectual activity with lower Alzheimer’s-related vulnerability. Findings included lower tau pathology, delayed mild cognitive impairment and dementia onset, and higher cognitive resilience.
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
A large analysis of 131,821 health professionals found that two to three cups of caffeinated coffee a day were linked to a 19 percent lower dementia risk. One daily cup of caffeinated tea was linked to a 14 percent lower risk.
Two studies of older adults with type 2 diabetes linked diabetic retinal disease with higher dementia risk. DME and more severe diabetic retinopathy were associated with higher all-cause and vascular dementia risk, but not consistently with Alzheimer’s disease.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
20/20 BioLabs began trading on Nasdaq under ticker AIDX and disclosed a contingent financing agreement of up to $40 million. It later signed an exclusive U.S. license deal with ROKIT to add CKD prediction to OneTest for Longevity.
Research and survey data point to lifelong learning, midlife stimulating activities and treatment of health risks as factors linked to better brain health and lower dementia risk.
A study of 2,282 adults aged 60 and older found anemia was associated with higher Alzheimer’s disease blood biomarkers and a 66% higher chance of developing dementia. The highest risk was seen in participants with both anemia and higher biomarker levels.
A major evidence review of 17 clinical trials involving more than 20,000 participants found anti-amyloid Alzheimer’s drugs had absent or trivial effects on cognitive decline and dementia. The review also said the drugs likely increase the risk of brain swelling and bleeding.
A new Cochrane review said anti-amyloid Alzheimer’s drugs show no clinically meaningful benefit, but many researchers said the analysis has major limitations. Newer evidence on lecanemab and donanemab and broader drug development efforts continue to shape the field.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07602582 |
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). |
NOT_YET_RECRUITING | PHASE3 |
| NCT07602283 |
Music for Pain and Dementia |
RECRUITING | NA |
| NCT07600684 |
Preventing Medication Mismanagement in People Living With Dementia |
RECRUITING | NA |
| NCT07595666 |
Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region. |
ENROLLING_BY_INVITATION | NA |
| NCT07581639 |
Comparison of Live and Virtual Music-based Interventions in Mitigating Stress |
COMPLETED | NA |
| NCT07563777 |
100-Year Human Aging Study |
RECRUITING | |
| NCT07558785 |
Telemedicine Self-examination of Speech and Memory for Rapid Detection of Cognitive Impairments Using Machine Learning Methods |
ENROLLING_BY_INVITATION | NA |
| NCT07546708 |
The Black Immigrant Project |
RECRUITING | NA |
| NCT07545473 |
Retinal Hyperspectral Imaging in Neurodegenerative Diseases |
RECRUITING | NA |
| NCT07543341 |
Adapting Behavioral Interventions for Dementia to Address NCDs and Mental Health |
COMPLETED | NA |
